MarketsandMarkets Gen-Next Probiotics and Microbiome Congress

February 6 - 7, 2020 | Sheraton San Diego Hotel & Marina
CONFERENCE SPEAKERS
Advisors
David Kyle
David Kyle
Executive Chairman and CSO,
Evolve BioSystems, Inc


Dr. Kyle, a 35-year veteran of biotechnology has co-founded biotech companies in the field of infant nutrition including Martek Biosciences. At Martek, he led R&D and Commercial Development for over 15 years and today Martek’s DHA and ARA are now found in virtually every infant formula around the world. In 2000 he co-founded the US Chapter of the Mother and Child Foundation, an organization headquartered in London dedicated to better health of pregnant women and their children through better nutrition.  In 2013, David joined Evolve BioSystems as CEO and led the Company through several private equity financings and became Chairman of the Board in 2017.  David combines a distinguished scientific background with commercial acumen, has published over 70 scientific articles, edited two books, is the named inventor on over 200 patents, and was inducted into the US Technology Hall of Fame in 2009, for his contributions to Science and Industry.


Maya Ivanjesku
Maya Ivanjesku
Chief Scientific Officer,
Dakota Biotech


Maya holds Master of Science in Chemistry from Polytechnic University Brooklyn, NY. She has dedicated over twenty years of her career to the pharmaceutical, cosmeceutical and biotech industries formulating and launching products to market. Prior to creating LaFlore®, Maya held key senior leadership and R&D product development positions at many leading brands in the skincare industry, including: Estée Lauder, Clinique, Bobbi Brown, Origins, Aveda, TooFaced, Laura Mercier, Urban Decay, Smashbox, Nars, Benefit, MAC, Arbonne and many more.

Her expertise in manufacturing, quality and technology have been a great base in establishing Dakota Biotech’s own manufacturing facility, implementing quality systems and creating patented technologies.


Bharath Prithiviraj
Bharath Prithiviraj
Microbiology Lead scientist,
Ahara Biosciences, Inc



Speakers
Shailendra Singh (Shelly)
Shailendra Singh (Shelly)
Chief Operating Officer,
MarketsandMarkets


Shailendra Singh (Shelly) is Chief Operating Officer of MnM and a member of its board. He focuses on global sales and client services functions, as well as commercial optimization at MarketsandMarkets. He has years of expe¬rience in global delivery and outsourcing sector in the IT/ Consulting/Analytics/Big Data sectors. Prior to MnM, he was leading the global sales, client services and commercial ef¬fectiveness functions for Mu Sigma, a unicorn company and a leading global provider of Decision Sciences and Big Data analytics solutions.


Maya Ivanjesku
Maya Ivanjesku
Chief Scientific Officer,
Dakota Biotech


Maya holds Master of Science in Chemistry from Polytechnic University Brooklyn, NY. She has dedicated over twenty years of her career to the pharmaceutical, cosmeceutical and biotech industries formulating and launching products to market. Prior to creating LaFlore®, Maya held key senior leadership and R&D product development positions at many leading brands in the skincare industry, including: Estée Lauder, Clinique, Bobbi Brown, Origins, Aveda, TooFaced, Laura Mercier, Urban Decay, Smashbox, Nars, Benefit, MAC, Arbonne and many more.

Her expertise in manufacturing, quality and technology have been a great base in establishing Dakota Biotech’s own manufacturing facility, implementing quality systems and creating patented technologies.


Michael Bush
Michael Bush
President & CEO,
Prenexus Health


Michael Bush is the president and CEO of prebiotic manufacturer, Prenexus health.  Previously Michael was the president and CEO of the leading probiotic manufacturer, Ganeden, which was sold to Kerry in 2017.  Michael is also a board member for several for and not-for-profit organizations, including Executive Board Member of the International Probiotics Association (IPA).


Ellie Hang Trinh
Ellie Hang Trinh
Founder and Co-Owner,
Skin Probiotics by Skin Recovery, LLC



Seth Crosby
Seth Crosby
Director, Research Collaborations,
Washington University School of Medicine


Seth Crosby is the Director of Science Collaboration in the Department of Genetics at Washington University.  Crosby works with groups within and outside the University to leverage technology to achieve research and clinical goals.  He has been at Washington University for 16 years. During that time, he directed the Department of Genetics Microarray Core, which is now part of GTAC and then GTAC, itself, during its first two years.  Prior to that he was the Director of Translational Research at the Genome Center (now the McDonnell Genome Institute). Prior to his tenure at Washington University, Dr. Crosby worked in the field of genomics and drug discovery at Abbott Laboratories, Pfizer and Pharmacia.


Bharath Prithiviraj
Bharath Prithiviraj
Microbiology Lead scientist,
Ahara Biosciences, Inc



Chris Callewaert
Chris Callewaert
Postdoctoral Research Fellow,
Knight lab at University of California


Dr. Chris Callewaert holds two masters and a PhD from Ghent University, Belgium. Now he is a postdoctoral research fellow of the Research Foundation - Flanders (FWO) at Ghent University, Belgium and postdoctoral research associate in the Rob Knight lab at University of California, San Diego, USA. He studies the skin microbiome and metabolome in health and disease and is specialized in body odor in relation to the microbiome. He is the first one to try to solve body odor by replacing bacteria of smelly people with those of non-smelly people. He has conducted several clinical trials in this area. His research led to multiple peer-reviewed publications and was presented at several national and international conferences. He presented a TED talk and results of his research can be found on www.DrArmpit.com.


Larry Weiss
Larry Weiss
CEO and Founder,
Persona Biome, Inc.


Larry Weiss is the CEO and Founder of Symbiome (formerly Symbiome), a San Francisco skin microbiome company.  Previously, he was Chief Medical Officer at AOBiome where he formulated and developed the Mother Dirt cosmetics, including AO Mist, the first live skin probiotic. He has an extensive background in natural products chemistry, microbiology, clinical medicine, dermatology, and pharmaceutical and cosmetic product development. He is board-certified in Anesthesiology, has an MD from Stanford University, and a BS in Biochemistry from Cornell University. He has multiple patents and publications in the areas of chemistry, electrophysiology, clinical pharmacology, and the microbiome. He is also a Co-Founder of CleanWell Company.


Jennie Starr
Jennie Starr
Director of Marketing ,
BioForm Solutions



Ross Youngs
Ross Youngs
CEO & Founder,
Biosortia Pharmaceuticals


Ross O. Youngs, Founder and CEO - Mr. Youngs has over 30 years of inventing products, technologies and processes for a variety of industries. Mr. Youngs holds over 75 patents worldwide and is driven to innovate by a focus on better, faster and less expensive. Recent major innovations have included an R&D 100 Award for collaboration on biopolymer technologies. In 2009, the Company was awarded a $6 million ARPA-E (U.S. Dept. of Energy R&D) grant for its algal harvesting technology which helped lead to the development of Biosortia’s drug discovery platform. In 1998, Mr. Youngs was awarded the Ernst & Young Ohio Entrepreneur of the Year award and the U.S. Small Business Administration honored Mr. Youngs as their national “Business Person of the Year” in a presentation made by Vice President Al Gore. 


Chuck Collins
Chuck Collins
Professor,
East Tennessee State University



Christopher Ellis
Christopher Ellis
Sr. Staff Scientist ,
OAK Ridge National Laboratory


Chris Ellis is a senior staff scientist Oak Ridge National Laboratory and executive director of the Microbiome of Idiopathic Neurodegenerative Diseases (MIND) consortium. Chris has pioneered a number of new methodologies in microbiome research including developing the first tools to explore the eukariome with next generation sequencing. As a computational microbiologist he is focused on devolving computational tools coupled new wet lab methodologies to explore the functional role of the microbiome in neurodegenerative disease and cancer. Currently, he is leading a multi-institutional effort called the MIND consortium to explore the role of the microbiome in the onset and progression Alzheimer’s, Parkinson’s disease, and ALS. His lab is applying machine learning and explainable AI in these diseases to better understand the causative agents of neurodegenerative disease.


Peter Leighton
Peter Leighton
CEO,
ProSperity Bioscience


Peter Leighton is the CEO of ProSperity Bioscience, engaged in the development and marketing of functionally targeted probiotic consumer products. Leighton is also the founder of Abunda, an integrated consulting practice. His 30+ years of executive experience at the intersection of consumer products and life science technology has leveraged emerging scientific research & discovery into engaging consumer brands. He has identified and executed novel marketing & commercialization strategies leading to the successful development and launch of hundreds of new products.

Leighton has been a guiding light to entrepreneurial enterprises and companies facing a challenge. In the early 2000’s he orchestrated a 300% increase in stock valuation and sales growth at Natrol (NTOL). He is a seasoned steward of innovation and strategic marketing, and a thought leader in the area of probiotics and functional foods. Leighton’s ability to identify emerging opportunities and create solutions has proven profitable for many of his clients and transformative for the industry.

Leighton has held senior executive positions including VP Product Strategy at Complete Nutrition, CEO at Advana Science, VP Marketing & Product Development at Natrol (NTOL), Vice President at Galileo Laboratories, VP Marketing at Metabolife, SVP Marketing at Weider Nutrition (WNI) and Director of Marketing at InterHealth Nutraceuticals.


Rosemarie Truman
Rosemarie Truman
Founder and CEO,
The Center for Advancing Innovation Inc.



Tony Lialin
Tony Lialin
Chief Commercial Officer,
Loop Genomics



Momchilo Vuyisich
Momchilo Vuyisich
Founder and Chief Science Officer,
Viome, Inc


Momo Vuyisich is a co-founder and Chief Science Officer at Viome, a data-driven personalized nutrition company. Momo provides scientific leadership at Viome and his vision is to revolutionize healthcare from "symptoms management" to a true preventative medicine. He leads product development, clinical test implementation, and comprehensive clinical research portfolio. Momo is also an Adjunct Professor at the University of New Mexico and New Mexico Tech. Before co-founding Viome in 2016, Momo spent 12 years at Los Alamos National Laboratory, where he led the Applied Genomics team, which developed the core technology used by Viome today.


Gregory Lambert
Gregory Lambert
CEO and VP Research and Development,
TargEDys


Pharmacist and Ph.D. in pharmaceutical technology, Gregory LAMBERT carrier is split between Biotech and Pharma where he occupied the positions of Chief Scientific Officer and Chief Executive Officer. Gregory drove the development of several products from the concept to market authorizations. Gregory has joined the scientific founders of TargEDys as CEO in 2014.


Sujash Chatterjee, PhD.
Sujash Chatterjee, PhD.
Genomics Application Specialist,
QIAGEN


He has almost 15 years of experience in genomic profiling methods including microarrays/RNA-seq; assay development; and molecular/ cell biology techniques. Currently he leads technical support for NGS projects in areas of Biomarker Discovery, Microbial/ Metagenomics and HT Single Cell Sequencing for QIAGEN’s bio-pharma and academic customers on the West Coast. Formerly, as a Asst. Director for Science and Engineering Research Center at University of Houston, he built and led a NGS Core team that contributed to projects including The Cancer Genome Atlas (NIH-TCGA), NASA’s first single cell studies and deep soil microbiome mapping. Additionally, he has been part of drug discovery and biotech business development teams.


Eric Huang
Eric Huang
Professor,
University of California San Diego


Eric is currently working as the Professor at the University of California, San Diego. He is the Chair Professor National Central University. He was the Chairman of the Department of Biomedical Sciences and Engineering at National Central University. He has acted as a visiting faculty in different universities like National Central University, Mongolian National University of Medical Sciences, Chengdu Second People’s Hospital & Fudan University.

In the year 2004-5 he acted as the Co-director, Skin Proteomics Core of UAB Skin Disease Research Center. In the year 2015, he was honored as the Chair Professor in the Foundation for The Advancement of Outstanding Scholarship and was also honored with Research Grant Award by Dermatology Foundation/USA and Galderma International Award in the year 2009.


M. Andrea Azcarate-Peril
M. Andrea Azcarate-Peril
Director, Microbiome Core Facility,
University of North Carolina


M. Andrea Azcarate-Peril, Ph. D. is Associate Professor of Medicine, GI Division in the School of Medicine at UNC Chapel Hill.  She is also the founding and current Director of the UNC Microbiome Core, which provides research and technical support to investigators interested in addressing the roles of the host-associated microbiota in health and disease.

Dr. Azcarate-Peril is a microbiologist by training and has extensive experience in the characterization of complex microbial populations and functional metagenomics using culture-dependent and culture-independent methods including Next Generation Sequencing. Her research projects have focused on functional genomics of probiotics and gut microbiome modulation by prebiotics for over 20 years, resulting in over 70 peer-reviewed publications.

Dr. Azcarate-Peril’s current projects aim to define modulators of the gut microbiome capable of reversing dysbioses induced by age, diet and nutritional behaviors. She is particularly interested in the development of application-directed probiotic strains to address and prevent gastrointestinal disorders.


Arun Bhunia
Arun Bhunia
Professor of Food Microbiology,
Purdue University


Prof. Arun K. Bhunia received his Bachelor of Veterinary Science (BVSc) degree from India, PhD from the University of Wyoming (USA), and postdoctoral training from the University of Arkansas (USA). He is a professor of food microbiology in the Department of Food Science and is also affiliated with the Department of Comparative Pathobiology, Purdue Institute of Inflammation, Immunology and Infectious Disease (PI4D), and Purdue University Life Science program (PULSe). He is chair of the Interdepartmental Food Science Graduate Program. His expertise is in the area of microbial pathogenesis (host-pathogen interaction), probiotic bioengineering and foodborne pathogen detection. To date, he has co-authored more than 188 research publications, 2 textbooks (Fundamental Food Microbiology; Foodborne Microbial Pathogens–Mechanisms and Pathogenesis), edited 4 books, and delivered over 140 talks. He served in the USDA National Advisory Committee on Microbiological Criteria for Foods (NACMCF; 2013-2017) and has received Purdue Agriculture Research Award (2003), Purdue Faculty Scholar (2005), Purdue Team Award (2006), IFT R&D Award (2009), Outstanding Graduate Educator Award at Purdue (2013), Fulbright Specialist (2016-2021), and Maurice Weber Laboratorian Award from IAFP (2017).


A. Bruce Johnson
A. Bruce Johnson
PhD, Corporate Vice President, Business Development,
Phibro Animal Health Corporation


After completing graduate degrees in Animal Nutrition at the University of Illinois and Oklahoma State University, Dr. Johnson joined the research faculty at Texas A&M University as Assistant Professor.  He left academia to become Group Leader, Field Research and Technical Services for Roche Animal Health and Nutrition. He moved on from there to become Director, Global Research and Nutritional Services for Zinpro Corporation for 13 years growing the group in both number and global prominence.  He returned to DSM to become Director, External Business Development, North and South America for over 7 years. For the past 8 years, he has been Corporate Vice President, Global Business Development for Phibro Animal Health Corporation.  He holds responsibility for sourcing, expanding and developing Phibro’s various commercial platforms by acquiring intellectual properties, patents, technologies, development of new products, and acquisition of scientifically focused companies.  He was responsible for the recent acquisition of Osprey Biotechnics, a leading specialty microbial fermentation company based in Sarasota, Florida.


Katrine Whiteson
Katrine Whiteson
Associate Director, UCI Microbiome Initiative,
University of California


Dr. Katrine Whiteson is an Assistant Professor at University of California Irvine and the Associate Director of the recently launched UCI Microbiome Initiative. She studied Biochemistry at UC Berkeley (BA, 2000) and University of Chicago (PhD, 2007). She first had the opportunity to study human-associated microbes at the University of Geneva Hospitals in 2008. Her lab at UCI studies the human microbiome in health and disease. This has them hunting for bacteria, fungi and viruses in feces, sewage, sputum and other well-loved samples - the students are brave! Their favorite study designs are longitudinal, and they use metabolomics and sequencing along with in vitro culturing and experimental evolution to study the microbes, their metabolites.


Shikha Snigdha
Shikha Snigdha
Director Of Innovation,
MeriCal LLC


Dr. Snigdha is the Director of Innovation at MeriCal and brings to the group an expertise in dietary interventions and how they impact the human body. She has a PhD in Pharmaceutical Innovation, and a Master’s Degree in Biomedical Sciences.  She has over 10 years of experience working on diet and nutrition and has led both preclinical and clinical research on development of dietary supplements including probiotics.  Her work includes product development for several pharmaceutical companies including Schering Plough, Organon and GSK.

Her specific expertise is nutritional research and life-style interventions to promote healthy aging. She has published over 20 papers, 2 book chapters and a patent during the course of this work and has provided scientific opinion for various stages of product development including conceptualization, formulation, and innovation in the probiotic space.  Dr. Snigdha is driving the search for new ingredients and application for probiotic strains in her current role at MeriCal.


Yu-Jui Yvonne Wan
Yu-Jui Yvonne Wan
Professor and Vice Chair for Research, Department of Pathology and Laboratory Medicine,
University of California, Davis


Dr. Wan received her B.S. from the School of Pharmacy at Taipei Medical University in Taipei, Taiwan in 1979. She received her M.S. in 1981 and her Ph.D. in 1983 in Experimental Pathology from Drexel University.  She obtained a fellowship from NIH to study molecular biology of the liver before she became a faculty member in the Pathology Department at Harbor UCLA in 1989, and became a Full Professor in 2001.

As Vice Chair of Research for the Department of Pathology & Laboratory Medicine at the University of California, Davis, Dr. Wan oversees research activities of our faculty members and advances the department’s strategic research plan. Dr. Wan is actively involved in service at the national and international levels. She has been serving NIH study sections continuously for the past 17 years.  She is currently serving as Editor-in-Chief for Open Pharmaceutical Science Journal as well as an editorial board member for many other journals.


Sarah M. Allard
Sarah M. Allard
Assistant Project Scientist ,
Gilbert Lab


Dr. Sarah Allard is an Assistant Project Scientist at the University of California San Diego, where she works at the forefront of microbiome research and innovation. Sarah received her PhD in Plant Science from the University of Maryland and remained at UMD for a postdoctoral fellowship with CONSERVE in the Maryland Institute of Applied Environmental Health. There, her research focused on crop, soil, and water microbiomes in the context of food safety and environmental change. Previously she worked at the US Food and Drug Administration’s Center for Food Safety and Applied Nutrition, where her research led to the patent of a biological control agent for on-farm food safety. In her current role in the Gilbert lab, Sarah is exploring how microbiome research can be harnessed to support environmental recovery, safe and productive food systems, and the betterment of human health.


Dr. Sabine Hazan
Dr. Sabine Hazan
Founder/ CEO,
ProgenaBiome, Ventura Clinical Trials, Malibu Specialty Center


Dr. Sabine Hazan, acclaimed physician and founder of ProgenaBiome, LLC, Ventura
Clinical Trials, LLC, and Malibu Specialty Center, is at the forefront of medicine. Dr. Hazan was
the first woman accepted into the University of Florida as a Clinical Gastroenterology Fellow,
and has continued to be a pioneer in medicine. She has recently turned her focus to Fecal
Microbiota Transplant, also known as FMT. A process by which the gut is recolonized with the
necessary beneficial flora, which have dramatic impact on overall health. Due to the results she
observed with FMT, she opened ProgenaBiome to better understand the gut flora and disease.
Spearheading advancement in medicine, this treatment is being explored by Dr. Hazan
following the leadership of Dr. Thomas Borody and the late Dr. Sydney Finegold to treat Crohn’s
disease, Autism, Celiac, Alzheimer’s, Alopecia Areata, Obesity, Psoriasis, Metastatic Cancer, and
recurrent infection with Clostridium difficile.


Dr. Gang Wang
Dr. Gang Wang
CEO,
Nimble Science


Dr. Gang Wang is the Co-founder and CEO of Nimble Science. He holds a PhD in Biomedical Engineering from the University of Calgary. Dr. Wang has 8+ years of expertise in medical device research, development and commercialization. He was an award-winning biomedical engineering researcher with deep expertise in wearable and ingestible medical device development.


Tuval Ben-Yehezkel
Tuval Ben-Yehezkel
,
Loop Genomics


Dr. Ben-Yehezkel founded Loop Genomics in 2016 as part of the Y-Combinator accelerator in order to disrupt the long-read sequencing space. Prior to Loop Genomics Dr. Ben-Yehezkel was the CEO and co-founder of Synvaccine, a viral synthetic genome engineering company and a Senior Scientist at the Weizmann Institute of Science, where he developed methods for engineering synthetic organisms. At Loop Genomics, he is directing the development and commercialization of the first hardware-free synthetic long read sequencing technology that can be used for any sequencing application. Loop’s technology transforms short-read sequencers into single-molecule long-read sequencers, offering the accuracy and resolution required for precision Microbiome, Transcriptome and DNA sequencing

 


Dr. William Gerwick
Dr. William Gerwick
Director, NIH Training Grant on Marine Biotechnology,
University of California at San Diego


William H. Gerwick received his B.S. in Biochemistry (UC Davis, 1976), his Ph.D. in Oceanography (Scripps Institution of Oceanography, 1981), and did postdoctoral studies at the U. Connecticut (1981-82). He was Professor of Chemistry at the U. Puerto Rico (1982-84) and then moved to the College of Pharmacy, Oregon State U. as Professor of Pharmaceutical Sciences (1984-2005). In 2005 he became Professor of Oceanography and Pharmaceutical Sciences at Scripps Oceanography and the Skaggs School of Pharmacy, UC San Diego, and in 2011 was promoted to Distinguished Professor. He has received several awards and prizes, and is a Fellow of the American Association for the Advancement of Science (AAAS) and the American Society of Pharmacognosy. His research focuses on the discovery of novel natural products from marine cyanobacteria and algae, development of new methodologies in structure analysis, biomedical applications of marine natural products, and investigations of natural product biosynthesis.